Total Payments
$333,310
2024 Payments
$112,855
Companies
18
Transactions
332
Medicare Patients
326
Medicare Billing
$71,450
Payment Breakdown by Category
Consulting$277,231 (83.2%)
Travel$40,398 (12.1%)
Food & Beverage$6,240 (1.9%)
Research$5,459 (1.6%)
Other$3,318 (1.0%)
Education$663.99 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $277,231 | 81 | 83.2% |
| Travel and Lodging | $40,398 | 121 | 12.1% |
| Food and Beverage | $6,240 | 113 | 1.9% |
| Unspecified | $5,459 | 10 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,131 | 3 | 0.9% |
| Education | $663.99 | 2 | 0.2% |
| Grant | $186.86 | 2 | 0.1% |
Payments by Type
General
$327,851
322 transactions
Research
$5,459
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $90,925 | 78 | $0 (2024) |
| Janssen Research & Development, LLC | $51,925 | 55 | $0 (2024) |
| Celgene Corporation | $44,155 | 55 | $0 (2023) |
| Janssen Global Services, LLC | $39,182 | 42 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $32,977 | 22 | $0 (2024) |
| Gilead Sciences, Inc. | $15,863 | 22 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $14,282 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,529 | 8 | $0 (2020) |
| Amgen Inc. | $7,571 | 7 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $6,450 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,855 | 99 | Janssen Research & Development, LLC ($51,100) |
| 2023 | $36,656 | 37 | E.R. Squibb & Sons, L.L.C. ($12,291) |
| 2022 | $38,636 | 36 | Kite Pharma, Inc. ($21,615) |
| 2021 | $17,857 | 10 | Janssen Global Services, LLC ($8,750) |
| 2020 | $28,571 | 13 | Kite Pharma, Inc. ($11,900) |
| 2019 | $59,870 | 82 | Kite Pharma, Inc. ($31,147) |
| 2018 | $22,502 | 41 | Celgene Corporation ($18,397) |
| 2017 | $16,363 | 14 | Celgene Corporation ($10,091) |
All Payment Transactions
332 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $48.64 | General |
| Category: CELLT | ||||||
| 12/12/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $15.93 | General |
| Category: CELLT | ||||||
| 12/08/2024 | Janssen Global Services, LLC | DARZALEX (Drug), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 12/06/2024 | Janssen Global Services, LLC | DARZALEX (Biological), CARVYKTI, TALVEY | Food and Beverage | In-kind items and services | $39.40 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Global Services, LLC | DARZALEX (Biological), CARVYKTI, TALVEY | Food and Beverage | In-kind items and services | $9.64 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $73.54 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $594.79 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | In-kind items and services | $248.04 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $55.62 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $45.98 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $10,450.00 | General |
| Category: CELLT | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $181.26 | General |
| Category: CELLT | ||||||
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CELLT | ||||||
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CELLT | ||||||
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: CELLT | ||||||
| 11/08/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $638.95 | General |
| Category: CELLT | ||||||
| 10/15/2024 | Janssen Scientific Affairs, LLC | DARZALEX (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma (CRB-401) | Celgene Corporation | $2,866 | 1 |
| CRB-401 - CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $1,326 | 1 |
| A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL | Gilead Sciences, Inc. | $1,267 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 83 | 197 | $71,849 | $18,746 |
| 2022 | 4 | 139 | 284 | $106,095 | $27,915 |
| 2021 | 3 | 58 | 151 | $17,317 | $13,317 |
| 2020 | 2 | 46 | 139 | $14,675 | $11,472 |
Total Patients
326
Total Services
771
Medicare Billing
$71,450
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 159 | $58,194 | $14,770 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 17 | $7,565 | $2,139 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 21 | $6,090 | $1,837 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 171 | $60,534 | $13,689 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 58 | $16,820 | $5,622 | 33.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 27 | $16,281 | $4,574 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 28 | $12,460 | $4,030 | 32.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 119 | $11,958 | $9,710 | 81.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 16 | $3,137 | $2,091 | 66.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 16 | $2,222 | $1,515 | 68.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 113 | $11,689 | $9,498 | 81.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 17 | 26 | $2,987 | $1,974 | 66.1% |
About Dr. Yi Lin, M.D
Dr. Yi Lin, M.D is a Hematology & Oncology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285608174.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yi Lin, M.D has received a total of $333,310 in payments from pharmaceutical and medical device companies, with $112,855 received in 2024. These payments were reported across 332 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($277,231).
As a Medicare-enrolled provider, Lin has provided services to 326 Medicare beneficiaries, totaling 771 services with total Medicare billing of $71,450. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Rochester, MN
- Active Since 02/15/2006
- Last Updated 08/18/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285608174
Products in Payments
- Yescarta (Drug) $67,658
- CARVYKTI (Drug) $55,484
- DARZALEX (Drug) $12,447
- KYMRIAH (Biological) $10,529
- JCAR017 (Drug) $7,951
- BB-2121 (Drug) $7,356
- CARVYKTI (Biological) $4,925
- ABECMA (Biological) $3,235
- SARCLISA (Biological) $3,136
- OPDIVO (Biological) $2,648
- TECVAYLI (Biological) $2,160
- Kyprolis (Biological) $1,521
- Revlimid (Drug) $742.40
- DARZALEX (Biological) $329.47
- NO PRODUCT DISCUSSED (Drug) $86.00
- ELREXFIO (Drug) $43.39
- TUKYSA (Drug) $33.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
David Dingli, M.d, M.D
Hematology & Oncology — Payments: $505,158
Hematology & Oncology $505,158
Amit Mahipal
Hematology & Oncology — Payments: $474,204
Hematology & Oncology $474,204
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028
Dr. Alok Khorana, M.d, M.D
Hematology & Oncology — Payments: $205,803
Hematology & Oncology $205,803